Xilio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xilio Therapeutics, Inc. on June 13, 2024. The report details corporate governance changes effective as of the filing date. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices located in Waltham, Massachusetts.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of new directors and does not contain financial performance data.
Material Changes
Effective June 13, 2024, the Board of Directors increased its size to nine members. Two new directors were elected:
- James Shannon, M.D.: Elected as a Class I director with a term expiring at the 2025 annual meeting. Appointed to the Nominating and Corporate Governance Committee.
- Aoife Brennan, M.D.: Elected as a Class III director with a term expiring at the 2027 annual meeting. Appointed to the Audit Committee.
Both directors will receive compensation in accordance with the Company's standard arrangements for non-employee directors and will enter into standard indemnification agreements.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the director elections and related compensatory arrangements.
Key Facts for Investor Verification
- Verify the specific compensation amounts for non-employee directors as detailed in the Company's 2024 proxy statement filed on April 25, 2024.
- Confirm the qualifications and background of the newly appointed directors, Dr. James Shannon and Dr. Aoife Brennan.
- Review the Company's standard indemnification agreement (Exhibit 10.19 to the 2023 Form 10-K) to understand the liability protections for the new directors.
- Note that the Board size has expanded to nine directors, which may impact future governance decisions and committee compositions.